Cyclacel Pharmaceuticals Inc. Stock
With 12 Sell predictions and only 2 Buy predictions the community sentiment for Cyclacel Pharmaceuticals Inc. is rather negative.
On the other hand, the target price of 14 € is above the current price of 0.22 € for Cyclacel Pharmaceuticals Inc., so the potential is actually 6263.64%.
Our community identified positive and negative aspects for Cyclacel Pharmaceuticals Inc. stock for the coming years. 1 users see the criterium "EBIT Margin" as a plus for the Cyclacel Pharmaceuticals Inc. stock. On the other hand our users think that "Expected Cash Flow" could be a problem in the future.
Pros and Cons of Cyclacel Pharmaceuticals Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cyclacel Pharmaceuticals Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Cyclacel Pharmaceuticals Inc. | - | - | - | - | - | - | - |
Vaxart Inc. | -2.130% | -9.112% | 21.001% | -33.776% | 54.771% | -84.898% | - |
Larimar Therapeutics Inc. | -6.850% | 1.493% | 16.239% | 111.180% | 66.667% | -35.849% | -75.135% |
Jaguar Health Inc. | -7.440% | -50.627% | -25.442% | -82.106% | -21.788% | -99.957% | - |
Comments
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) had its price target lowered by analysts at Roth Mkm from $21.00 to $11.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat